Physician profile
Timothy E Cooper
NPI 1003860891
$947.70
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.43 | 2019 | |
| Novo Nordisk INC | $123.88 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $115.24 | 2019 | |
| Pfizer INC. | $98.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $82.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.37 | 2019 | |
| Astellas Pharma US INC | $55.20 | 2019 | |
| Allergan, INC. | $47.08 | 2019 | |
| Abbott Laboratories | $40.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.70 | 2019 | |
| Scilex Pharmaceuticals INC. | $34.60 | 2019 | |
| Therapeuticsmd, INC. | $34.33 | 2019 | |
| Lilly USA, LLC | $33.80 | 2019 | |
| Merck Sharp & Dohme LLC | $32.46 | 2019 | |
| Daiichi Sankyo INC. | $14.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.